News PharmAla Biotech receives guidance on new MDMA-like drug for PTSD and Autism The MHRA has confirmed that PharmAla's MDMA-like drug candidate ALA-002 does not require additional preclinical data Natalia Buendia CalvilloJuly 20, 2023
News PharmAla Biotech secures first purchase order for GMP LaNeo MDMA in Australia Patients in Australia can use psilocybin and MDMA as of July 1 Natalia Buendia CalvilloJuly 5, 2023
News PharmAla Biotech receives $50K grant for AI drug discovery The grant will bolster PharmAla's use of in-silico modelling Natalia Buendia CalvilloJune 9, 2023
News PharmAla Biotech and Vitura Health form joint psychedelics venture in Australia To help the new venture get started, Vitura has agreed to provide up to $2.2 million in loans Natalia Buendia CalvilloMay 2, 2023
Medical and Pharmaceutical PharmAla Biotech and Filament Health partner to release MDMA capsules The capsules are GMP certified and will be used in clinical trials and by authorized patients Natalia Buendia CalvilloApril 11, 2023